APA (7th ed.) Citation

YY, J., A, K., J, X., S, L., JP, M., LS, W., . . . SY, R. (2025). Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: Health-related quality-of-life analysis from the randomized KEYNOTE-811 trial. ESMO open, 10(10), 105542. https://doi.org/10.1016/j.esmoop.2025.105542

Chicago Style (17th ed.) Citation

YY, Janjigian, et al. "Pembrolizumab with Trastuzumab and Chemotherapy for HER2-positive Advanced Gastric Cancer: Health-related Quality-of-life Analysis from the Randomized KEYNOTE-811 Trial." ESMO Open 10, no. 10 (2025): 105542. https://doi.org/10.1016/j.esmoop.2025.105542.

MLA (9th ed.) Citation

YY, Janjigian, et al. "Pembrolizumab with Trastuzumab and Chemotherapy for HER2-positive Advanced Gastric Cancer: Health-related Quality-of-life Analysis from the Randomized KEYNOTE-811 Trial." ESMO Open, vol. 10, no. 10, 2025, p. 105542, https://doi.org/10.1016/j.esmoop.2025.105542.